Business Wire

Turkey’s Zer Recognized as “Product Challenger” in Global Procurement Ecosystem

4.4.2022 12:00:00 EEST | Business Wire | Press release

Share

Zer , a Turkey-based company specializing in strategic procurement and sourcing management, has been included – for the first time – on the prestigious Provider Lens™ Quadrant Report of Information Services Group (ISG), a leading global technology research and advisory firm. Updated on a quarterly basis, ISG Provider Lens™ is a practitioner-led service provider comparison, empowered by ISG’s advisory experience and data-driven research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220401005382/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

For the first time, Turkish procurement services firm Zer has been listed on ISG’s Provider Lens™ Quadrant Report (Photo: Business Wire)

A subsidiary of Turkey's Koç Group, Zer took its place in ISG Provider Lens™ report in both the “Procurement BPO Services” and the “Digital Transformation Services” quadrants for both large accounts and midmarket categories. Zer featured in the same quadrant with the firms who consult to industry giants on Fortune 50.

Zer's brand Promena, which is a strategic procurement software, meanwhile, also made the list (in the “Software Platforms and Solutions” quadrant for large accounts), taking a place alongside globally-recognized service providers.

‘Closely followed by procurement professionals’
According to Zer General Manager Mehmet Apak, ISG’s Provider Lens List is extremely influential in the competitive world of digital solutions. “It is closely followed by supply chain and procurement professionals from all over the world,” Apak says. “Lists like ISG Provider Lens™ serve to raise brand awareness in international markets and enhance Turkey's role in the global procurement ecosystem.”

Underlining that global demand for Promena had recently increased by 50%, Apak went on to assert that “Zer’s inclusion in the ISG Provider Lens™ “is a natural reflection of the qualities we bring to all stakeholders – qualities such as resilience and agility.” Both these qualities are crucial, he adds, “in a business environment that is increasingly unpredictable and in which priorities are constantly changing.”

A ‘Value Leader’ in the global procurement sector
Zer‘s strategic procurement software Promena has also been recognized by SpendMatters, Capgemini, Capterra, Procurement Leaders, Art of Procurement and Sourceforge, all of which follow top digital solutions and procurement brands. Since 2019, Promena was included in SpendMatters’ influential Solutionmap Report. Last year, the same report described the company as a “Value Leader” in the global procurement sector.

“We’re pleased that our company is drawing international attention,” Apak says. “In the digital age, procurement and supply chain management is more essential than ever. It lets businesses connect with the rest of the world, keep costs and risks in check, and overcome the hurdles associated with digital transformation.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tülay Genç
support@b2press.com
+90 (212) 635 70 68

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye